List view / Grid view
20 October 2025 | By
The balance between speed, scale, and compliance has never been more critical. As GLP-1s, biosimilars, and advanced therapies reshape global priorities, pharma leaders face a new question: how can manufacturing infrastructure evolve fast enough to keep pace?
20 October 2016 | By Adeyinka Aina and Chris Edlin, Pharmaceutical Manufacturing Technology Centre
Swabbing is a technique commonly used during pharmaceutical cleaning protocols to ensure that the cleaning process meets both safety and regulatory requirements; this allows for the cleaning process to be subsequently verified and validated1-7.
The manufacture of sterile medicinal and therapeutic products increasingly calls for aseptic processing using barrier separation technology comprising isolators and restricted access barrier systems (RABS) that have glove-sleeve systems.
In a healthcare world that experiences a plethora of high-cost new therapies coming to market in parallel with price increases for existing speciality drugs, pharmaceutical companies are having to move away from traditional pricing models that are largely based on demand and what the market will bear. At the same…
17 October 2016 | By Rebecca Hill, TheLawFirm.com
Read Injury Lawyer Rebecca Hill's review on how Big Pharma's money is affecting our health and our wallets and the suggestions for change...
11 October 2016 | By Vanessa Rieu and Annsley Merelle Ward
Vanessa Rieu and Annsley Merelle Ward explain how life sciences companies can leverage their knowledge of national patent laws in a post-Brexit Europe...
3 October 2016 | By Peter Brady, CEO Orbital Media and Dr Martin Goldman, independent medical officer, Iatros Consulting
Dr Martin Goldman joins Peter Brady, Orbital Media's CEO, to discuss how to untap the potential of social media sourced real world evidence...
27 September 2016 | By Dominic Adair and Emma Muncey, Bristows
Top litigators Dominic Adair and Emma Muncey review patent court cases to identify the legal steps you should take when marketing a biosimilar...
20 September 2016 | By Ernest Loumaye, MD, PhD, Co-Founder & Chief Executive Officer, ObsEva
Ernest Loumaye, PhD, Co-Founder & Chief Executive Officer of ObsEva discusses the unmet need of women's reproductive health and what's in the pipeline for treatment...
15 September 2016 | By Niamh Louise Marriott, Digital Content Producer
European Pharmaceutical Review caught up with Destiny Pharma’s CEO, Dr Love, for an exclusive interview to discuss why the pharmaceutical industry needs to radically change its approach to antibiotics in order to combat the threat of bacterial resistance…
13 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Following an article about the worrying presence of E.coli in UK supermarkets, our sister title New Food caught up with Emma Rose from Alliance to Save Our Antibiotics for an exclusive interview discussing the latest issues facing antibiotic resistance…
5 September 2016 | By Stuart Goodman, Blue Latitude Health
Blue Latitude Health's Stuart Goodman discusses the latest progress in Alzheimer's disease research and treatment to find out why a cure remains elusive...
31 August 2016 | By Niamh Louise Marriott, Digital Content Producer
In April of this year, NICE started to assess the cost and clinical effectiveness of every drug currently in the old cancer drugs fund...
In this issue: Regulation, Environmental Monitoring, Drug Delivery; Microbiology, Track & race, Spectroscopy, HPLC, Mass Spectrometry, and much more...
Biosimilars are becoming increasingly important in the European Union’s biopharmaceutical landscape due to the increased growth of biologicals as key therapies and the financial pressure this puts on healthcare budgets.
24 August 2016 | By European Pharmaceutical Review
In this Environmental Monitoring In-Depth Focus: Bacterial endotoxin contamination and testing limits in ophthalmics; The basics of environmental monitoring in aseptic units; Environmental Monitoring Roundtable...
